Genenta Science Secures $20M to Propel Next-Generation Immuno-Oncology Innovations

We are thrilled to announce that Genenta Science (Nasdaq: GNTA) has successfully raised $20,000,000 in our latest funding round, marking a pivotal moment in our journey towards transforming cancer immunotherapy. As a clinical-stage immuno-oncology company, Genenta is spearheading the development of a proprietary hematopoietic stem cell therapy designed to treat a variety of solid tumor cancers. Our flagship product candidate, Temferon™, is innovatively engineered to enable the expression of immune-therapeutic payloads within the tumor microenvironment by harnessing bone marrow–derived myeloid cells. This groundbreaking approach aims to elicit a durable and targeted immune response against tumors, potentially overcoming the challenges of immune tolerance. The recent capital infusion will primarily drive the advancement of our clinical pipeline, with a particular focus on expanding our trials and exploring novel therapeutic combinations. Following the completion of a Phase 1 trial in newly diagnosed Glioblastoma Multiforme patients—a study that hinted at the reprogramming of the tumor microenvironment and disruption of myeloid-induced tolerance—the funds will support the initiation and accelerated development of our Phase 1/2a metastatic Renal Cell Carcinoma study. This new trial, slated to combine our treatment with immune checkpoint inhibitors, aims to further validate the therapeutic versatility and efficacy of our one-time monotherapy approach, which holds promise not only as a standalone treatment but also in enhancing the performance of other approved therapies. This funding milestone reinforces our commitment to pioneering therapeutic innovations in oncology and solidifies our position as a leader in next-generation cancer treatment solutions. We are excited to harness these new resources to expedite clinical development and ultimately improve outcomes for patients battling life-threatening cancers.